热门资讯> 正文

Artiva Biotherapeutics GAAP每股收益为-22.00美元

2024-08-30 04:25

Artiva Biotherapeutics, Inc.(ARTV) 0
Lineage(LINE) 0

Artiva Biotherapeutics press release (NASDAQ:ARTV): Q2 GAAP EPS of -$22.00.
As of June 30, 2024, Artiva had cash, cash equivalents, and short-term investments of $46.6 million. In addition, Artiva completed its IPO in July 2024 in which it sold 14,920,000 shares of its common stock, including partial exercise of the overallotment option, for gross proceeds of $179.0 million.

More on Artiva Biotherapeutics

Artiva: Natural Killer Cell Biotech With First Half Of 2025 Lupus Treatment Data
IPO Roundup: Lineage, OneStream Software, and more
Artiva Biotherapeutics surges on trading debut
Historical earnings data for Artiva Biotherapeutics
Financial information for Artiva Biotherapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。